Cladis Investment Advisory’s iShares Biotechnology ETF IBB Stock Holding History

Cladis Investment Advisory’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$891K	Sell	5,275 -100	-2%	-$17.1K	0.49%	67
2025 Q4	$907K	Sell	5,375 -50	-0.9%	-$8.12K	0.5%	64
2025 Q3	$783K	Sell	5,425 -285	-5%	-$38.9K	0.45%	67
2025 Q2	$722K	Hold	5,710	–	–	0.45%	67
2025 Q1	$730K	Buy	5,710 +570	+11%	+$77.3K	0.53%	59
2024 Q4	$680K	Buy	5,140 +840	+20%	+$118K	0.48%	64
2024 Q3	$626K	Buy	4,300 +1,265	+42%	+$183K	0.43%	68
2024 Q2	$417K	Buy	3,035 +115	+4%	+$15.4K	0.3%	88
2024 Q1	$401K	Buy	+2,920	New	+$399K	0.29%	90

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cladis Investment Advisory's IBB Position: Q1 2026 in Review

Cladis Investment Advisory reduced its iShares Biotechnology ETF (IBB) stake by 1.9% in Q1 2026, selling an estimated $17.1K and leaving 5,275 shares worth $891K. The position accounts for 0.49% of the portfolio, ranked #67.

Cladis Investment Advisory first reported a position in IBB in Q1 2024 and has held it in 9 quarters since. The position peaked at $907K in Q4 2025. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Cladis Investment Advisory held 5,275 shares of iShares Biotechnology ETF worth $891K as of Q1 2026.
Cladis Investment Advisory sold 100 iShares Biotechnology ETF shares in Q1 2026, an estimated $17.1K.
iShares Biotechnology ETF made up 0.49% of Cladis Investment Advisory's portfolio in Q1 2026, its #67 holding.
Cladis Investment Advisory first reported a position in iShares Biotechnology ETF in Q1 2024 and has held it in 9 quarters since.
Cladis Investment Advisory's iShares Biotechnology ETF position peaked at $907K in Q4 2025.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Cladis Investment Advisory's 13F filing for Q1 2026, filed 15 May 2026.